spacer
home > epc > autumn 2017 > qualified matters
PUBLICATIONS
European Pharmaceutical Contractor

Qualified Matters

Clinical trials are conducted in research settings, designed to answer specific questions about biomedical or behavioural interventions, including new treatments – such as novel vaccines, drugs, dietary choices and supplements and medical devices – as well as known interventions that warrant further study and comparison. They generate critical data on safety and efficacy, which is then submitted to the regulatory authorities responsible for vetting the risk versus benefit ratio of the trial.

As the demand for new therapies and treatments persists, the need for clinical studies expands globally. This comes with a growing need for organisations to ensure they are able to design, start up and execute their trials, thus delivering critical information regarding the results.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Marquard Lett is Senior Advisor at UL Compliance to Performance and has over 38 years’ experience in highly regulated industries, including the pharma industry in manufacturing, training and qualification systems, training quality systems and business and manufacturing process improvement.

Gordon Elger
is Senior Advisor at UL Compliance to Performance and has more than 30 years’ experience in the pharma industry in R&D, manufacturing, regulatory affairs, compliance and document management. He has been responsible for regulatory submissions and liaison with agencies at scientific advice meetings, leading the design and implementation of document management systems and is fully conversant with GxP requirements. Email: gordon.elger@ul.com
spacer
Marquard Lett
spacer
spacer
spacer
Gordon Elger
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI Annual Reports - how accurate were they 5 years on?


More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

PPMA Show 2017

26-28 September 2017, NEC, BIRMINGHAM UK

The PPMA is the UK's trade association for suppliers of processing and packaging machinery to the UK market and represents over 500 member and associate companies. Its principle objective is to promote sales of machinery, both at home and abroad, through various projects and services of mutual benefit to both members and their customers by providing free technical and machinery information and advice.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement